Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
– Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data.